NCT05948462
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05948462 |
| Title | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC) |
| Acronym | NSCLC |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | SCRI Development Innovations, LLC |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
CKB BOOST